Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

BACKGROUND: Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial. We sought to assess the glycemic effects of sacubitril/valsartan in heart failure with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijkman, Magnus O., Claggett, Brian, Vaduganathan, Muthiah, Cunningham, Jonathan W., Rørth, Rasmus, Jackson, Alice, Packer, Milton, Zile, Michael, Rouleau, Jean, Swedberg, Karl, Lefkowitz, Martin, Shah, Sanjiv J., Pfeffer, Marc A., McMurray, John J. V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206286/
https://www.ncbi.nlm.nih.gov/pubmed/35717169
http://dx.doi.org/10.1186/s12933-022-01545-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206286/
https://www.ncbi.nlm.nih.gov/pubmed/35717169
http://dx.doi.org/10.1186/s12933-022-01545-1

Ejemplares similares